Continuing Education New Advances in JAK Inhibitors and non-JAK Inhibitors in Myelofibrosis: Updates from ASH 2023 Earn CME, CE

Newsletter Updates on Combination Therapies and Future Directions in Myelofibrosis Haris Ali, MD and Andrew Kuykendall, MD Dr. Ali and Dr. Kuykendall share their perspectives on combination therapies that will have an impact on future clinical practice in MF.   Read More

Newsletter Updates on JAK inhibitors in Myelofibrosis Newsletter Stephen T. Oh, MD, PhD Dr. Oh discusses updates on JAK inhibitors, a pivotal drug class in the treatment of myelofibrosis.   Read More

Continuing Education Meeting Highlights in Myelofibrosis from the ASH Annual Meeting Andrew Kuykendall, MD; Stephen T. Oh, MD, PhD; and Haris Ali, MD

Continuing Education New and Emerging Directions in Myelofibrosis Treatment: Seeking to Improve Quality of Life and Prolong Survival Srdan Verstovsek, MD, PhD; Rami S. Komrokji, MD; Pankit Vachhani, MD

Continuing Education Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

Continuing Education Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies Prithviraj Bose, MD; and Andrew Kuykendall, MD

Continuing Education Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response Prithviraj Bose, MD; and John Mascarenhas, MD

FAQ Other than cytopenias, what are signs that my patient is intolerant to ruxolitinib or a JAK inhibitor? Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

FAQ What are the updates from ASH regarding new treatments or new data for patients with myelofibrosis? John O. Mascarenhas, MD

What are MPNs? What are Myeloproliferative neoplasms (MPNs)?

FAQ Can we predict which patients will respond to a JAK inhibitor? Andrew Kuykendall, MD and Prithviraj Bose, MD

FAQ As a clinician, what should guide my decision on which second-line therapy to choose for my patients? Prithviraj Bose, MD

FAQ What key defining point should community providers be aware of when looking at patients considered to have failed ruxolitinib or have achieved only suboptimal response? John Mascarenhas, MD View all FAQs